< Back to topics
> Cover Page, Authors, Institutions
> Purpose/Objective
> Materials/Methods
> Results/Discussion
> Conclusions
> View tables/images/videos
> View abstract & virtual poster in original format
|
|
Conclusions:
Overall, the prognosis for prostate cancer patients treated with brachytherapy and who remain free from disease for at least five years is excellent, with a 10-year FFPF rate of 96%. The 5-year PSA value is prognostic and patients with values <0.1 are unlikely to develop subsequent biochemical relapse. In addition, the fact that the disease-specific survival for all patients in this study was 100% and that no patient developed metastatic disease suggests that any residual disease in patients who remain FFPF for five years is most likely indolent in nature and is unlikely to have a significant impact on mortality.
|
|
